Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05868525 · ClinicalTrials.gov registry record · Phase 4
Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).
A Phase 4 study of Blunt Cerebrovascular Injury, sponsored by Loma Linda University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
- 1
- Study location
NCT05868525: Recruiting Phase 4 study of Blunt Cerebrovascular Injury, sponsored by Loma Linda University.
NCT05868525 is a Phase 4 study of Blunt Cerebrovascular Injury that is actively recruiting participants, run by Loma Linda University. The registered enrollment target is 98 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05868525, a Phase 4 study of Blunt Cerebrovascular Injury, is actively recruiting participants, sponsored by Loma Linda University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg. * If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.
Conditions Studied
Interventions
- DRUG Aspirin 325Mg Tab, Aspirin 81Mg Tab
Study Locations (1)
California
- Loma Linda University Medical Center - Loma Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2023-08-23 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What NCT05868525 shows while recruiting
NCT05868525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Blunt Cerebrovascular Injury appearing as the primary indexed condition, and to 1 intervention - of which Aspirin 325Mg Tab, Aspirin 81Mg Tab is the first listed.
NCT05868525 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05868525 about?
NCT05868525 is a clinical study titled "Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).". The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessel...
What is the current status of trial NCT05868525?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2023-08-23. Estimated completion is 2026-12.
What conditions does trial NCT05868525 study?
This clinical trial studies the following conditions: Blunt Cerebrovascular Injury.
What interventions are being tested in trial NCT05868525?
The interventions under investigation include: Aspirin 325Mg Tab, Aspirin 81Mg Tab (DRUG).
Who is sponsoring clinical trial NCT05868525?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05868525 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05868525's enrollment target sits among peer trials
98 854th of 2000 higher than 1,141 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI